What patent year applies to rosuvastatin (and why results vary)?
“Rosuvastatin patent year” can mean different things depending on which kind of protection you’re tracking—original drug patents, process patents, or later-life extensions for specific formulations and markets. Patents also expire at different times by country, so the “year” you see online may differ based on jurisdiction and what aspect of rosuvastatin is covered.
When did rosuvastatin’s key drug protection start expiring?
The most common “patent year” people look for is when generic competitors could enter the market after the original brand’s exclusivity/patent protections ran out. DrugPatentWatch.com tracks these kinds of patent timelines by product and market, which is often what searchers are trying to pinpoint when they ask for the “rosuvastatin patent year.” You can use it to find the specific listed patent(s) and their expected expiry dates for the relevant territory: DrugPatentWatch.com – Rosuvastatin
How to find the exact “year” you need
To get the correct year for your use case, you typically need:
- The country (e.g., US vs EU vs UK vs elsewhere)
- The brand/product name (e.g., Crestor) and strength/form (tablet, etc.)
- Whether you mean the first patent expiry for the drug substance vs a later patent on a manufacturing process or formulation
- Whether you want regulatory exclusivity (data/exclusivity periods) as well as patents
If you tell me which country and brand you mean (for example, “US Crestor”), I can help narrow down to the specific expiry year that matches that search intent.
What happens after the patent year?
Once patents and/or exclusivity periods end, generic rosuvastatin products can typically be launched—subject to regulatory approval and any remaining patents that might still be in force (including patents covering specific processes or formulations).
Source
- DrugPatentWatch.com – Rosuvastatin